In good news for J-pod, killer whale calf is a female
VANCOUVER — The Centre for Whale Research says it has confirmed a new killer whale calf in a pod of endangered orcas that live off southwest British Columbia is female.
It's a piece of good news for J-pod, after the recent death of another calf whose mother pushed the carcass for days in what researchers said was a display of grief.
The Washington state-based organization says on social media that the new calf known as J62 was seen on Feb. 8 off the San Juan Island, and researchers were able to photograph her belly and confirm her sex.
The group says the calf appears to be doing well and is "filling out nicely."
The centre has previously said that new females are important for southern resident killer whales as they are "largely limited by the number of reproductively aged females."
The post this week also says researchers were able to confirm the adult female J35, or Tahlequah, is no longer carrying the body of her dead calf, which she started pushing around Jan. 1.
Researchers have previously said the behaviour is an apparent act of grief, and that J35 has now lost two of her four documented calves.
She captured headlines worldwide when she pushed the remains of another calf for 17 days in 2018.
This report by The Canadian Press was first published Feb. 19, 2025.
The Canadian Press
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
20-05-2025
- Hamilton Spectator
Nova Scotia-shot ‘Washington Black' to make summer premiere on Disney Plus
TORONTO - The limited series adaptation of Esi Edugyan's 2018 Giller Prize-winning novel 'Washington Black' will arrive on Disney Plus this summer. The streaming service says it has marked July 23 for the premiere of all eight episodes of the sprawling Nova Scotia-shot series. 'Washington Black' tells the story of George Washington Black, an 11-year-old slave who unexpectedly escapes a Barbados sugar plantation with the help of the owner's kinder brother, an ambitious inventor. The scientist sees himself in Black and wants the boy to act as his assistant while he builds a flying machine. The series stars Ernest Kingsley Jr., Rupert Graves and Sterling K. Brown, who's also credited as one of its executive producers. 'Washington Black' followed Edugyan's Giller Prize-winning 2011 novel 'Half-Blood Blues,' and was shortlisted for the Booker Prize, the Rogers Writers' Trust Fiction Prize and the American Library Association's Carnegie medal for fiction. This report by The Canadian Press was first published May 20, 2025.
Business Wire
16-05-2025
- Business Wire
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising CNS Uptake at American Society of Gene and Cell Therapy
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR') announced today that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene therapy research programs at the American Society of Gene and Cell Therapy (ASGCT) 28 th Annual Meeting, being held May 13-17, 2025, in New Orleans, LA. In an oral presentation, the JCR researcher reported that the Company's proprietary J-Brain Cargo ® (JBC) technology enables the efficient delivery of an adeno-associated virus (AAV) gene therapy across the blood-brain barrier (BBB) and into the central nervous system (CNS) in mice, monkeys, and several animal models of CNS diseases. We have successfully developed JUST-AAV, a novel AAV vector platform technology designed to enhance targeted delivery and reduce liver tropism, thereby improving safety and efficacy of AAV-based gene delivery technologies to the CNS. JUST-AAV encompasses a range of vector types optimized for various target tissues, including liver-sparing, muscle-targeting, and brain-targeting variants. This proprietary technology holds significant promise for advancing the field of AAV-based gene therapy. 'These findings represent a significant advancement toward new treatments for previously challenging CNS diseases,' said Hiroyuki Sonoda, Ph.D., Director, Senior Managing Executive Officer, and Executive Director, Research Division at JCR Pharmaceuticals. 'Our preclinical data demonstrate that our brain-targeting JUST-AAV technology delivers therapeutic agents to the central nervous system far more efficiently than conventional AAV9, while significantly reducing liver accumulation. This enhanced safety profile greatly increases the potential for clinical translation. This research is a crucial step in our ongoing commitment to developing innovative solutions for unmet medical needs.' JCR showcased the following presentation: Incorporation of transferrin receptor binder and surface mutations into AAV enables efficient brain delivery and reduced liver tropism Presenter: Yuhei Ashida (JCR Pharmaceuticals) Researchers successfully created a brain-targeting AAV vector (brain-targeting JUST-AAV) by incorporating a miniaturized antibody that binds to the transferrin receptor, into the AAV capsid. Furthermore, unique modifications to the AAV capsid sequence significantly reduced AAV vector accumulation in the liver, a known source of adverse effects. In mouse studies, the JUST-AAV vector achieved 77-fold higher expression of green fluorescent protein (GFP) in the brain compared to AAV9, while reducing the tropism to the liver by 99%. To further enhance brain targeting and BBB permeability, the researchers incorporated additional molecules that bind to receptors other than the transferrin receptor into the AAV capsid. In monkey studies, this bispecific vector demonstrated an improved gene delivery efficiency to the brain by several orders of magnitude compared with AAV9, while reducing infection in potentially problematic tissues such as the liver and dorsal root ganglia by more than 90%. Application of JUST-AAV to a mouse model of neuronal ceroid lipofuscinosis resulted in the disappearance of symptoms such as seizures and prolonged lifespan to an extent of a functional cure. These results suggest that the newly developed JUST-AAV technology offers the potential for safer and more efficient gene therapy than conventional gene delivery vectors. About the American Society of Gene and Cell Therapy (ASGCT) The American Society of Gene and Cell Therapy (ASGCT) is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. The mission of the ASGCT is to advance knowledge, awareness, and education, leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. For more information, please visit www. About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier (BBB)-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system (CNS). The first drug developed based on this technology is IZCARGO ® (INN: pabinafusp alfa) and was approved in Japan for the treatment of a lysosomal storage disorder. JUST-AAV JUST-AAV is a proprietary platform technology that utilizes modified adeno-associated virus (AAV) vectors. The technology entails insertion of miniaturized antibodies against receptors on selected tissues, organs or the blood-brain barrier onto the capsid surface, enhancing targeted delivery to those tissues and organs. Further capsid modifications minimize off-target effects and improve safety. The name is derived from ' J CR' ' U ltimate destination of organ' ' S afeguarding against off-target delivery' and ' T ransformative technology' reflecting its potential for broad application across various diseases. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.
Yahoo
12-05-2025
- Yahoo
HistoSonics secures first insurance coverage for histotripsy system
US-based HistoSonics has secured the first major insurance coverage for its histotripsy system, amid media speculation of a $2.5bn sale. Healthcare payor Blue Cross Blue Shield of Michigan (BCBSM) and health plan option Blue Care Network have created a new medical policy that covers non-thermal histotripsy using the HistoSonics' Edison system for the treatment of primary and metastatic liver tumours. The policy coverage took effect on 1 February 2025, giving 4.5 million residents in Michigan early access to the treatment if eligible. A broader policy will go into effect on 1 July 2025. The coverage is a win for the treatment modality as HistoSonics looks to grapple for market share amongst more established surgical techniques. Founded in 2009 with technology developed by the University of Michigan, HistoSonics received US Food and Drug Administration (FDA) approval in October 2023 for its Edison system, which uses short pulses of focused ultrasound energy to mechanically destroy and liquefy affected tumours. The therapy, which is delivered via a robotic arm, does not carry the same invasiveness or toxicity as traditional approaches. Edison is the only FDA-approved histotripsy system currently on the market. A 12-month follow-up analysis from the HOPE4LIVER study demonstrated a 90% local tumour control rate observed across all treated tumours, regardless of type or origin. This, HistoSonics says, compares favourably to the current standard of care of local regional therapies at the one year follow-up mark. Current surgical approaches used to kill liver tumours include radiofrequency ablation, microwave ablation, and cryoablation. The company is conducting further clinical trials to expand the system's use into kidney and pancreatic cancer treatment. The Edison system has been adopted at over 50 medical centres in the US to treat over 1,500 patients. 'Liver tumours are often a leading cause of death for patients with serious cancers, and it's critical that they have access to safe, effective and non-invasive treatment options,' said HistoSonics' CEO Mike Blue. 'This milestone marks an important precedent, and we expect additional states and payers to follow in expanding access to histotripsy for patients with liver tumours across the US.' The coverage is set against a backdrop of acquisition talk, with the Financial Times reporting that major medtech companies are eyeing the histotripsy specialist. Medtronic, GE HealthCare, and Johnson & Johnson (J&J) are all reported to be evaluating the business. Through its investment arm, J&J has been a long-time backer of HistoSonics, the latest cash injection occurring via the participation in a $102m Series D round in August 2024. "HistoSonics secures first insurance coverage for histotripsy system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
